Enolen's fast track designation by the FDA aims to expedite its development for localized prostate cancer treatment, addressing unmet medical needs. The localized delivery technology targets ...
HLD-0915 has received FDA fast track designation for mCRPC, expediting its development and review process to address unmet medical needs. Halda Therapeutics is conducting a phase 1/2 clinical trial to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results